Arrowhead to Request FDA Priority Review for Plozasiran in Severe Hypertriglyceridemia

Arrowhead Pharmaceuticals plans to request FDA priority review status for its drug Plozasiran to treat severe hypertriglyceridemia, signaling potential expedited regulatory approval and market entry.

This Wire brief sits within Fusion42's coverage of Biotech.